## Maria Cristina JanuÃ;rio Santos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/192321/publications.pdf Version: 2024-02-01



Maria Cristina JanuÃirio

#	Article	IF	CITATIONS
1	Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease. Brain, 2005, 128, 2260-2271.	7.6	114
2	G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Movement Disorders, 2005, 20, 1653-1655.	3.9	106
3	Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion, 2008, 8, 219-228.	3.4	102
4	Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiology of Aging, 2009, 30, 1515-1517.	3.1	97
5	The Impact of Mitochondrial Fusion and Fission Modulation in Sporadic Parkinson's Disease. Molecular Neurobiology, 2015, 52, 573-586.	4.0	79
6	Fibroblasts of Machado Joseph Disease patients reveal autophagy impairment. Scientific Reports, 2016, 6, 28220.	3.3	68
7	Retinal texture biomarkers may help to discriminate between Alzheimer's, Parkinson's, and healthy controls. PLoS ONE, 2019, 14, e0218826.	2.5	54
8	Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients. Biochemical and Biophysical Research Communications, 2008, 374, 599-603.	2.1	53
9	Mitochondrial-dependent apoptosis in Huntington's disease human cybrids. Experimental Neurology, 2010, 222, 243-255.	4.1	53
10	Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. BMC Neurology, 2008, 8, 1.	1.8	52
11	Bioenergetic dysfunction in Huntington's disease human cybrids. Experimental Neurology, 2011, 231, 127-134.	4.1	52
12	Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington's disease carriers. Mitochondrion, 2013, 13, 801-809.	3.4	39
13	Ubiquitin proteasome system in Parkinson's disease: A keeper or a witness?. Experimental Neurology, 2012, 238, 89-99.	4.1	37
14	The role of the basal ganglia in implicit contextual learning: A study of Parkinson's disease. Neuropsychologia, 2009, 47, 1269-1273.	1.6	36
15	Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. Science Translational Medicine, 2020, 12, .	12.4	32
16	Motion integration deficits are independent of magnocellular impairment in Parkinson's disease. Neuropsychologia, 2009, 47, 314-320.	1.6	28
17	The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm. Molecular Neurobiology, 2015, 52, 1804-1820.	4.0	25
18	Tau and neurofilament lightâ€chain as fluid biomarkers in spinocerebellar ataxia type 3. European Journal of Neurology, 2022, 29, 2439-2452.	3.3	25

Maria Cristina JanuÃirio

#	Article	IF	CITATIONS
19	Specific retinotopically based magnocellular impairment in a patient with medial visual dorsal stream damage. Neuropsychologia, 2006, 44, 238-253.	1.6	22
20	Clinical Features of Machado-Joseph Disease. Advances in Experimental Medicine and Biology, 2018, 1049, 255-273.	1.6	21
21	Specific impairment of visual spatial covert attention mechanisms in Parkinson's disease. Neuropsychologia, 2011, 49, 34-42.	1.6	18
22	Scanning Patterns of Faces do not Explain Impaired Emotion Recognition in Huntington Disease: Evidence for a High Level Mechanism. Frontiers in Psychology, 2012, 3, 31.	2.1	18
23	Parametric fMRI of paced motor responses uncovers novel wholeâ€brain imaging biomarkers in spinocerebellar ataxia type 3. Human Brain Mapping, 2016, 37, 3656-3668.	3.6	16
24	Tremor Frequency Assessment by iPhone® Applications: Correlation with EMG Analysis. Journal of Parkinson's Disease, 2016, 6, 717-721.	2.8	15
25	Automatic classification of idiopathic Parkinson's disease and atypical Parkinsonian syndromes combining [ <sup>11</sup> C]raclopride PET uptake and MRI grey matter morphometry. Journal of Neural Engineering, 2021, 18, 046037.	3.5	15
26	Classification of Huntington's disease stage with support vector machines: A study on oculomotor performance. Behavior Research Methods, 2016, 48, 1667-1677.	4.0	14
27	Implicit Contextual Learning in Prodromal and Early Stage Huntington's Disease Patients. Journal of the International Neuropsychological Society, 2012, 18, 689-696.	1.8	13
28	A Novel Ecological Approach Reveals Early Executive Function Impairments in Huntington's Disease. Frontiers in Psychology, 2019, 10, 585.	2.1	12
29	Reliability and Validity of 39-Item Parkinson's Disease Questionnaire and Parkinson's Disease Quality of Life Questionnaire. Acta Medica Portuguesa, 2017, 30, 395-401.	0.4	11
30	Substantia nigra hyperechogenicity does not correlate with motor features in Parkinson's disease. Journal of the Neurological Sciences, 2016, 364, 9-11.	0.6	9
31	Transcranial Sonography and DaTSCAN in Early Stage Parkinson's Disease and Essential Tremor. European Neurology, 2016, 76, 252-255.	1.4	8
32	Impulsivity across reactive, proactive and cognitive domains in Parkinson's disease on dopaminergic medication: Evidence for multiple domain impairment. PLoS ONE, 2019, 14, e0210880.	2.5	8
33	The effect of impulsivity and inhibitory control deficits in the saccadic behavior of premanifest Huntington's disease individuals. Orphanet Journal of Rare Diseases, 2019, 14, 246.	2.7	7
34	A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	7
35	The concept of meaning: The key to clarify the human cognition and psychopathology. Medical Hypotheses, 2015, 84, 268-272.	1.5	5
36	Visual and ocular motor function in the atypical form of neurodegeneration with brain iron accumulation type I. British Journal of Ophthalmology, 2018, 102, 102-108.	3.9	5

#	Article	IF	CITATIONS
37	Cognition, function and awareness of disease impact in early Parkinson's and Huntington's disease. Disability and Rehabilitation, 2022, 44, 920-938.	1.8	5
38	Posterior reversible encephalopathy syndrome: the importance of early diagnosis. BMJ Case Reports, 2012, 2012, bcr2012006852-bcr2012006852.	0.5	4
39	"Pinball―intrusions in spinocerebellar ataxia type 3. Neurology, 2018, 90, 36-37.	1.1	4
40	Hereditary spastic paraparesis: The real-world experience from a Neurogenetics outpatient clinic. European Journal of Medical Genetics, 2022, 65, 104430.	1.3	4
41	Parkinson's Disease and Mitochondrial DNA NADH Dehydrogenase Subunit 1 Nucleotides 3337–3340: Study in a Population from the Central Region of Portugal (Coimbra). European Neurology, 2003, 50, 60-61.	1.4	3
42	Parkinson's disease with hypocalcaemia: adult presentation of 22q11.2 deletion syndrome. BMJ Case Reports, 2018, 2018, bcr-2017-223751.	0.5	3
43	Tremor modulations across periods with and without voluntary motion and limb load task demands using movement quantification. , 2013, 2013, 4338-41.		2
44	Classification of Huntington's Disease Stage with Features Derived from Structural and Diffusion-Weighted Imaging. Journal of Personalized Medicine, 2022, 12, 704.	2.5	2
45	Protocol for the Characterization of the Cytosine-Adenine-Guanine Tract and Flanking Polymorphisms in Machado-Joseph Disease. Journal of Molecular Diagnostics, 2020, 22, 782-793.	2.8	1
46	Cognition and meaning. Medical Hypotheses, 2016, 94, 57.	1.5	0